Novo Nordisk A/S (NYSE:NVO) Posts Earnings Results, Beats Estimates By $0.19 EPS

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Wednesday. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.77 by $0.19, Zacks reports. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. The firm had revenue of $11.98 billion during the quarter, compared to analysts’ expectations of $10.89 billion.

Here are the key takeaways from Novo Nordisk A/S’s conference call:

• Q2 sales rose 7% to DKK 78.5 billion at constant exchange rates, while adjusted operating profit increased 11%, driven by GLP-1 volume growth and cost discipline.
• The Wegovy pill launch showed strong momentum, reaching approximately 1.5 million global users and capturing about 90% of the U.S. oral obesity-treatment market; early launches in the U.K. and UAE also expanded Novo’s obesity market share.
• Despite volume growth, lower realized prices and access pressures remain significant, particularly in the U.S., where Wegovy injectable sales declined 22% at constant exchange rates and self-pay growth came at lower price points. Novo also expects intensifying competition, Medicaid coverage reductions, and semaglutide patent expiries to weigh on results.
• Novo raised its 2026 outlook, now expecting adjusted sales and operating profit growth of 0% to -6% at constant exchange rates, while cautioning that second-half headwinds include adverse comparisons, loss of exclusivity, pricing pressure, and continued investment.
• The ZEUS cardiovascular outcomes trial for ziltivekimab failed to reduce major adverse cardiovascular events, with a hazard ratio of 0.99, and showed more serious infections; however, Novo plans to continue related cardiovascular studies and advance its broader obesity and diabetes pipeline.

Novo Nordisk A/S Trading Up 3.0%

Shares of Novo Nordisk A/S stock traded up $1.35 during mid-day trading on Thursday, hitting $45.88. 9,016,207 shares of the stock were exchanged, compared to its average volume of 18,247,344. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The stock has a market capitalization of $204.88 billion, a price-to-earnings ratio of 11.23, a price-to-earnings-growth ratio of 4.03 and a beta of 0.76. The company has a 50-day simple moving average of $46.96 and a 200 day simple moving average of $45.12. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be issued a $0.5786 dividend. This represents a yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is 42.54%.

Hedge Funds Weigh In On Novo Nordisk A/S

Institutional investors and hedge funds have recently modified their holdings of the company. Transamerica Financial Advisors LLC grew its stake in Novo Nordisk A/S by 201.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock worth $31,000 after acquiring an additional 403 shares during the period. Johnson Financial Group Inc. increased its position in Novo Nordisk A/S by 128.0% during the third quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock worth $38,000 after purchasing an additional 384 shares during the last quarter. T. Rowe Price Investment Management Inc. purchased a new position in Novo Nordisk A/S during the fourth quarter worth approximately $41,000. Quattro Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 4th quarter valued at $44,000. Finally, State of Wyoming boosted its holdings in shares of Novo Nordisk A/S by 72.7% in the 2nd quarter. State of Wyoming now owns 950 shares of the company’s stock valued at $66,000 after purchasing an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Q2 earnings beat and higher guidance: Adjusted revenue increased 7% year over year and operating profit rose 11%, while Novo raised its full-year sales and operating-profit outlook for the second time. Growth was supported by GLP-1 volume gains, international markets and obesity care. Novo Nordisk raises adjusted sales and adjusted operating profit outlook for 2026
• Positive Sentiment: Semaglutide demand remains substantial: Wegovy and Ozempic continue to drive growth, with the oral Wegovy product reportedly exceeding 5 million U.S. prescriptions since launch. The company also highlighted accelerating demand for the pill and expects continued GLP-1 momentum. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: Patent protection win: A Dutch court issued a preliminary injunction against compounded semaglutide nasal spray, ordering the supplier to stop infringing activities and remove product listings. The ruling could help protect Novo’s branded semaglutide franchise from unauthorized alternatives. Novo Nordisk wins Dutch court injunction
• Neutral Sentiment: Capital return: Novo announced a dividend of 0.5786 per share, payable August 25 to shareholders of record August 17. The reported 254% yield appears inconsistent with the payment amount and current share price, so investors should verify the figure with the company or broker. Novo Nordisk dividend information
• Negative Sentiment: Pipeline concerns overshadow results: A setback for next-generation obesity candidate CagriSema and broader worries about the strength of Novo’s development pipeline have kept investors focused on long-term growth rather than the improved 2026 forecast. Novo Nordisk’s raised forecast fails to change the debate over its obesity business
• Negative Sentiment: Pricing and competitive pressure: Lower U.S. prices, patent-loss risks and Eli Lilly’s stronger-than-expected GLP-1 performance are raising concerns that Novo may lose market share or experience margin pressure in the second half. The divide between Eli Lilly and Novo Nordisk is widening

Wall Street Analyst Weigh In

NVO has been the subject of several research analyst reports. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, July 6th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and issued a $47.00 price target on shares of Novo Nordisk A/S in a report on Thursday. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $65.81.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.